Skip to main content
Clinical Trials/NCT03229993
NCT03229993
Completed
Not Applicable

The Safety and Efficacy of OCT in the Evaluation and Treatment of Angiographically Borderline Coronary Artery Lesions

The First Affiliated Hospital with Nanjing Medical University1 site in 1 country220 target enrollmentDecember 31, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Optical Coherence Tomography (OCT)
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Enrollment
220
Locations
1
Primary Endpoint
MACEs
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

To find out the safety and efficacy of Optical Coherence Tomography (OCT) in the evaluation and treatment of angiographically borderline coronary artery lesions in a Chinese population, and to compare the effectiveness of OCT versus SPECT in treating such subjects. All the participants included in the study will be those that are found to have borderline coronary artery lesions on coronary angiography, in whom the investigators feel that OCT will be useful to assess whether PCI will be of benefit to the treatment of the lesion pathology, or whether optimal medical therapy is the most appropriate treatment modality. Those participants who declined OCT will be offered SPECT as an alternative method to assess and treat the borderline coronary artery stenosis.

It is estimated that OCT guided "PCI or not" has a non-inferiority to SPECT's in the borderline coronary artery stenosis.

Registry
clinicaltrials.gov
Start Date
December 31, 2017
End Date
December 31, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • The inclusion criteria for this study will be only those participants in whom diagnostic coronary angiography revealed borderline coronary artery lesion. These participants will undergo the OCT procedure, or alternatively ECT.

Exclusion Criteria

  • Exclusion criteria will be those participants with previous cardiogenic shock, stroke, renal dysfunction, and acute or chronic total occlusion coronary lesions.

Outcomes

Primary Outcomes

MACEs

Time Frame: 12 months

The incidence of major adverse cardiac events (MACEs) including death, myocardial infarction, and stent thrombosis.

TLR

Time Frame: 12 months

The incidence of target lesion revascularization (TLR)

Secondary Outcomes

  • Recurrent angina(12 months)
  • Rehospitalization(12 months)

Study Sites (1)

Loading locations...

Similar Trials